Nephrology

The patient-focused guidelines were developed by the American Kidney Fund and AstraZeneca to help people with CKD manage high potassium.

Findings suggest greater CTSS levels are associated with an elevated risk of IgAN and highlight the enzyme’s potential as a diagnostic biomarker.

Findings from a meta-analysis examining 12 trials including more than 70,000 patients with diabetes support combining SGLT2 inhibitors and GLP-1 RAs.

Gross hematuria due to infection was not associated with the incidence of gross hematuria due to vaccination in patients with IgAN who received COVID-19 mRNA vaccination.

Patients with chronic tonsillitis had greater IgAN event rates than those without, and further analysis revealed chronic tonsillitis was linked to a greater risk of developing IgAN.

Findings highlight the prognostic value of metabolic syndrome components in predicting both renal and cardiovascular outcomes in patients with IgA nephropathy.

This June 2024 month in review spotlights HCPLive’s coverage of the latest renal news and research in IgA nephropathy, differences in care, and novel associations in nephrology.

Findings highlight the potential utility of low-dose SGLT2 inhibitors for optimizing diabetes control and managing renal complications in pediatric patients with type 1 diabetes.

A Mendelian randomization analysis found co-localization between the target genes of SGLT2 inhibitors and the pathogenesis genes of membranous nephropathy and IgAN.

Findings suggest machine learning models may have promising utility in IgAN, highlighting the superior diagnostic performance of certain models versus standard logistic regression.

Lower free thyroxine levels were linked to worse renal outcomes in patients with IgAN, and free thyroxine with tubular atrophy/interstitial fibrosis had high predictive value for IgAN prognosis.

Survey results called attention to gaps in physicians’ clinical knowledge of IgAN, with incorrect responses prevalent among both specialists and generalists.

Results showed eGFR was linked to having ≥ 20 adult teeth in postmenopausal women, highlighting increased tooth loss among participants with CKD versus those without.

Data collected from parallel online surveys revealed notable differences in IgA nephropathy treatment among patients and nephrologists from the US, EU5, Japan, and China.

A post-hoc analysis of the phase 2b ORIGIN study highlights atacicept’s impact on hematuria, with more patients achieving improvement and resolution at 36 weeks than those on placebo.

Kaitlin Mayne, MBChB, discusses an analysis of the EMPA-Kidney trial examining the effects of multimorbidity, polypharmacy, and quality of life on effects of empagliflozin.

Alexandra Louise Møller, MS, PhD, discusses the results of a PROVALID analysis examining the predictive value of endotrophin levels for predicting CKD events.

In our nephrology month in review for May 2024, we spotlight the biggest news from the NKF and ERA meetings, including the latest updates in IgA nephropathy, C3 glomerulopathy, chronic kidney disease, and more!

Results suggest certain peroxiredoxins may be viable prognostic markers in glomerulopathies, including IgA nephropathy and membranous nephropathy.

Jonathan Barratt, MD, discusses a matching-adjusted indirect comparison of sparsentan and irbesartan against standard of care plus optimized RASI.

Fadi Fakhouri, MD, PhD, discusses the 1-year results of the NOBLE trial examining use of pegcetacoplan in patients with post-transplant C3G or IC-MPGN.

A phase 2b dose-finding study suggests use of clazakizumab was associated with a reduction in hs-CRP among patients undergoing maintenance dialysis.

Jonathan Barratt, MD, discusses the 52-week data from the phase 1/2 trial of zigakibart, which was presented at the 61st European Renal Association Congress.

A Q&A with David Kavanagh, MBChB, PhD, on the results of the APPEAR-C3G trial and implications for care moving forward.

The phase 2 NOBLE trial shows pegcetacoplan reduces disease activity in post-transplant C3G and IC-MPGN, with benefits persisting through the 40-week double-blind period.